Please login to the form below

Not currently logged in
Email:
Password:

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

German-based firm predicts savings after it unites the two biopharma companies

Fresenius

Fresenius Kabi has beefed up its pharmaceuticals division with deals to acquire US generic drugmaker Akorn for $4.3bn and Merck KGaA's fledgling biosimilars business for up to €670m ($730m).

The deal with Akorn bolsters Fresenius' drugs business - which is mainly focused on generic sterile injectable drugs - by adding capabilities in other categories such as ophthalmic, respiratory and intranasal drugs that are considered somewhat resistant to both generic competition and the current downward pressure in drug pricing, particularly in the US.

Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. Akorn is predicting that it will post around $1bn in sales this year and operating earnings of $363-401m, and Fresenius predicts that there will be cost savings of around $100m a year after the two companies are joined together.

The chief executive of Fresenius' US subsidiary, John Ducker, said merging the two companies would "strengthen and diversify both businesses” and that Akorn adds "specialised expertise in development, manufacturing and marketing of alternate dosage forms, as well as access to new customer segments like retail, ophthalmology and veterinary practices".

Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with the German company earlier this month. Fresenius has been steadily bolting on new acquisitions under new chief executive Stephan Sturm, buying Spanish hospital chain Quironsalud for €5.8bn last September.

The Merck agreement comes four years after Fresenius hived off its biotech business to the owners of Israeli group Neopharm, saying it wanted to narrow down its focus to intravenous drugs, infusion therapy, clinical nutrition and medical devices. Adding in Merck's biosimilars business takes it right back into the biotech sphere.

Fresenius is paying €170m upfront for the portfolio - headed by a copy of AbbVie's $16bn blockbuster Humira (adalimumab) that has reached the phase III trial stage in chronic plaque psoriasis - as well as €500m in milestones.

Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some big-selling products, and the move was considered a "plan B" to its usual focus on innovative drugs, said chief executive Stefan Oschmann recently.

Since then the company's R&D pipeline has picked up, and it has just had its first approval for Pfizer-partner immuno-oncology drug Bavencio (avelumab) in the US.

Article by
Phil Taylor

25th April 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics